Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of Abraxane (nab-paclitaxel), Gemzar (gemcitabine), and Avastin (bevacizumab)
that can be given to patients with advanced cancer. The safety of this drug combination will
also be studied.